Fate Therapeutics Inc
(STU:F6T)
€
2.915
0.144 (5.2%)
Market Cap: 332.29 Mil
Enterprise Value: 147.14 Mil
PE Ratio: 0
PB Ratio: 0.92
GF Score: 66/100 Fate Therapeutics Inc at Morgan Stanley Global Healthcare Conference Transcript
Sep 12, 2022 / 06:15PM GMT
Release Date Price:
€28.26
(+1.13%)
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst
Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Michael Ulz, one of the biotech analysts here. And it's my pleasure to introduce Scott Wolchko, President and CEO from Fate Therapeutics.
Just a reminder, format for today is a fireside chat. But before we get into the Q&A, I just need to read a quick disclaimer. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. And if you have any questions, please reach out to your Morgan Stanley sales representative.
And with that, we can dive right into the Q&A.
J. Scott Wolchko
Fate Therapeutics, Inc. - Founder, CEO, President & Director
Thank you.
Michael Eric Ulz
Morgan Stanley, Research Division - Equity Analyst
Welcome.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot